Quest Diagnostics Inc (DGX.N)

DGX.N on New York Stock Exchange

76.22USD
27 Mar 2015
Change (% chg)

$0.35 (+0.46%)
Prev Close
$75.87
Open
$75.69
Day's High
$76.33
Day's Low
$75.55
Volume
290,214
Avg. Vol
392,790
52-wk High
$78.23
52-wk Low
$54.92

DGX.N

Chart for DGX.N

About

Quest Diagnostics Incorporated (Quest Diagnostics) is a provider of diagnostic testing, information and services, providing insights that enable patients and physicians to make healthcare decisions. The Company’s operations are organized in two business groups, such as diagnostics information services and diagnostic solutions.... (more)

Overall

Beta: 0.63
Market Cap(Mil.): $10,999.41
Shares Outstanding(Mil.): 144.31
Dividend: 0.38
Yield (%): 1.99

Financials

  DGX.N Industry Sector
P/E (TTM): 20.13 24.51 40.78
EPS (TTM): 3.79 -- --
ROI: 7.37 7.09 16.19
ROE: 13.31 21.27 17.04
Search Stocks

Fitch Rates Quest Diagnostics' Bond Offering 'BBB'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, March 05 (Fitch) Fitch Ratings has assigned a 'BBB' rating to the $1.2 billion bond offering by Quest Diagnostics Inc. (Quest; NYSE: DGX). The Rating Outlook is Stable. A full list of ratings follows at the end of this release. Fitch expects the bond proceeds, as well as internal liquidity sources, to be used to repay up to $1,275 million of outstanding debt and associated fees during 2015, including: --$500 million of 5.45

05 Mar 2015

Myriad, Quest settle dispute over genetic cancer test

- Quest Diagnostics and Myriad Genetics have settled their patent dispute over genetic testing technology used to detect breast cancer.

09 Feb 2015

Quest in broad deal with CDC for hepatitis analysis

- Laboratory testing company Quest Diagnostics Inc said on Tuesday it had signed a $520,000 agreement with the Centers for Disease Control and Prevention to identify trends in screening, diagnosis and treatment of four strains of viral hepatitis.

27 Jan 2015

Quest says content with diagnostics, does not need CRO

- The chief executive of Quest Diagnostics Inc said his company will stick to its core business of diagnostic testing and is not interested in acquiring a contract research organization (CRO), despite such a planned move by rival diagnostics firm LabCorp .

05 Nov 2014

Earnings vs. Estimates

Search Stocks